Recursion Pharmaceuticals Inc. announced positive Phase 1b/2 results from the ongoing TUPELO trial evaluating REC-4881, an investigational allosteric MEK1/2 inhibitor, for the treatment of familial adenomatous polyposis (FAP). The results demonstrated rapid, substantial, and durable reductions in polyp burden in patients. The company is using its Recursion OS 2.0 platform, including large-scale real-world evidence analytics, to further advance the REC-4881 program. Recursion plans to engage with the FDA in the first half of 2026 to define a potential registration pathway and expand the eligible patient population and dosing schedule. The results from the clinical trial have already been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598312-en) on December 08, 2025, and is solely responsible for the information contained therein.